The latest Samsung Bioepis Biosimilar Market Report (Q2 2026) was released yesterday, and it reveals a host of intriguing movements in both price and market share of biosimilar agents. In this post, we’ll look at the oncology category.
The movements of one of the most established drug categories—trastuzumab—caught my eye in the newest release of the Samsung Bioepis Biosimilar Market Report. It perhaps highlights how the US drug pricing system seems to encourage strange market trends.
Biosimilars have been available in the category since 2020. One might expect the story of the trastuzumab biosimilar market to be stable and essentially straightforward. This is true when viewing market share data. Three products have shares of 24% and above: Kanjinti (31%), Trazimera (25%), and Ogivri (24%), and these shares have not moved much over the course of a couple of years. However, the average sales price (ASP) listings for these products are all over the map, and they are moving in wildly different directions.
The Case of Trazimera
Pfizer’s Trazimera is of particular interest. Based on the latest IQVIA data, the biosimilar’s ASP bounced up from $112 to $205 in the last quarter, after dropping a whopping 88% (from $938 to $112) in Q4 2025. Trazimera’s ASP is currently 80% below its nearest price competitor (Ontruzant).
On the opposite side of the scale, Kanjinti still has the highest ASP of any trastuzumab biosimilar, at more than 10 times the price of Trazimera, yet it is the market share leader (Table). For comparison, the reference product Herceptin has an ASP of $2,909, about 19% higher than Kanjinti’s but has only 3% market share, which is the only thing here that makes sense.
| Trastuzumab Biosimilar/Market Share | ASP Pricing | Percent Lower Than Current ASP of Reference Product |
| Trazimera (25%) | $205 | 93% |
| Ontrazant (2%) | $1,109 | 65% |
| Ogivri (24%) | $1,270 | 56% |
| Hercessi (3%) | $1,358 | 53% |
| Herzuma (2%) | $2,120 | 27% |
| Kanjinti (31%) | $2,135 | 27% |
| Data from Samsung Bioepis Biosimilar Market Report Q2 2026. | ||
Although this may be another case of a buy-and-bill product being preferred because of a higher price and thus higher reimbursement, it does not explain why Trazimera holds a full quarter of the total trastuzumab market. It could be that this is the product preferred by systems and practices being paid through value-based reimbursement, like shared savings. However, the other market leader, Ogivri, has a midrange ASP and a similar marketshare.
In the bevacizumab market, this appears not to be the case. Mvasi, with a 51% market share, has the lowest ASP. In the case of rituximab, Ruxience owns 39% of the market and is by far the lowest-priced agent. However, the second lowest-priced agent (Riabni) has only a 7% share, and Truxima, with a 31% share, costs three times as much as Ruxience.
In the next couple of posts, we’ll delve into some additional interesting biosimilar market share market trends, as described by the latest data.
This article was written by our Director of Content, Stanton Mehr. Stan has been writing commentary and reporting news about the biosimilar industry since the submission of the first biosimilar 351(k) application to the FDA 13 years ago. Since that time, BR&R has been tracking the US biosimilar marketplace, with the industry’s original, comprehensive and updated database of biosimilar filings with the FDA.
